Current research in the field of multiple myeloma

Current research in the field of multiple myeloma

VJHemOnc

3 years
459 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Mohamad Mohty, MD, PhD from Saint-Antoine Hospital, Paris, France discusses the current progress being made in multiple myeloma (MM) research. In frontline patients eligible for transplant, practitioners should aim to deepen the response rate and target minimal residual disease (MRD) before transplant. Prof Mohty suggests that second generation proteasome inhibitors are extremely potent in this setting and will be further strengthened by the addition of a monoclonal antibody, such as daratumumab, to achieve negative MRD status. In the transplant setting, current research is showing the importance of maintenance therapy. The meta analysis of three large randomised trials has shown an overall survival (OS) of 2.5 year overall as well as a relatively good safety profile. In the relapse setting current research is also showing positive results, specially in the use of daratumumab in combination with lenalidomide and dexamethasone. These combinations are achieving an impressive response when used earlier in the history of relapse, according to Prof Mohty. Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.
Up Next Autoplay
Loss of SETD2 is associated with dysregulation of protein translation in clear cell renal cell carcinoma
Loss of SETD2 is associated with dysregulation of protein translation in clear cell renal cell carcinoma
Category: Kidney Cancer
2 Views
kidneycancer 1 day
Immune Correlates and Prognostic Significance of CD73 Expression in Renal Cell Carcinoma
Immune Correlates and Prognostic Significance of CD73 Expression in Renal Cell Carcinoma
Category: Kidney Cancer
5 Views
kidneycancer 1 day
Using Epigenetic Therapy to Enhance Immunotherapy Response in RCC
Using Epigenetic Therapy to Enhance Immunotherapy Response in RCC
Category: Kidney Cancer
4 Views
kidneycancer 1 day
Radiation to Prime the Immune System
Radiation to Prime the Immune System
Category: Kidney Cancer
10 Views
kidneycancer 1 day
Therapeutic targeting of the extracellular matrix in kidney cancer
Therapeutic targeting of the extracellular matrix in kidney cancer
Category: Kidney Cancer
2 Views
kidneycancer 1 day
Innate Cytokines and Myeloid Cells
Innate Cytokines and Myeloid Cells
Category: Kidney Cancer
1 Views
kidneycancer 1 day
DNA Demethylation promotes ERV expression and activation of immune signaling in renal cell cancer cells
DNA Demethylation promotes ERV expression and activation of immune signaling in renal cell cancer cells
Category: Kidney Cancer
0 Views
kidneycancer 1 day
The T-cell response to Kidney Cancer
The T-cell response to Kidney Cancer
Category: Kidney Cancer
1 Views
kidneycancer 1 day
Discovery of new IO Targets Leveraging CRISPR
Discovery of new IO Targets Leveraging CRISPR
Category: Kidney Cancer
1 Views
kidneycancer 1 day
Patient-reported ECOG performance status (PS) is lower than oncologist-reported PS and is associated with worse psychosocial outcomes
Patient-reported ECOG performance status (PS) is lower than oncologist-reported PS and is associated with worse psychosocial outcomes
Category: Kidney Cancer
3 Views
kidneycancer 1 day